Skip to content
Peptigraph home

Tesamorelin for Heart Health: What the Evidence Shows

What human and animal studies show about Tesamorelin for heart health, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
Strongest evidence
Human RCT
Human studies
13
PubMed records, our ledger
Animal studies
0
PubMed records, our ledger
Studies we summarised
6
with an outcome for heart health

Evidence for heart health

Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Tesamorelin for heart health: outcomes in published studies
OutcomeResultStudy typeSource
Metabolic effect of VAT responseTesamorelin patients with an 8% or greater VAT reduction had better triglycerides, adiponectin and glucose homeostasis than nonresponders over 52 weeks.Human RCTClinical infectious diseases 2012, PMID 22495074
VAT, triglycerides and CRPTesamorelin reduced visceral fat without changing subcutaneous fat and improved triglycerides, C-reactive protein and carotid intima-media thickness without worsening glucose.Human RCTn = 60The Journal of clinical endocrinology and metabolism 2012, PMID 23015655
VAT and triglycerides at 52 weeksVAT change was sustained at -18% over 52 weeks, and triglycerides fell 51 mg/dl.Human RCTn = 410AIDS 2008, PMID 18690162
Triglycerides and cholesterol ratioTriglycerides fell 50 mg/dL with tesamorelin and rose 9 mg/dL with placebo; the total-to-HDL cholesterol ratio fell 0.31 versus a rise of 0.21.Human RCTn = 412The New England journal of medicine 2007, PMID 18057338
LipidsTriglycerides and the cholesterol-to-HDL ratio fell significantly with 2 mg versus placebo.Human RCTn = 61AIDS 2005, PMID 16052083
Total cholesterolTotal cholesterol improved modestly (mean difference -0.16 mmol/L).Meta-analysisn = 909Journal of the International Association of Providers of AIDS Care 2026, PMID 42538058

PubMed records for Tesamorelin and heart health: 13 human, 0 animal (search counts, not studies we reviewed). Grades follow our evidence scale.

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4Clinical infectious diseases 2012, PMID 22495074

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Other peptides people research for heart health

TirzepatideBPC-157
All peptides for heart health, compared

Common questions

Does Tesamorelin help with heart health?

The strongest study we summarise for heart health is human rct evidence, across 6 studies with an outcome for heart health. A trial result is not an approval; see the legal status.

Is Tesamorelin approved for heart health?

Tesamorelin is FDA approved (Egrifta). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for heart health?

There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.

More on Tesamorelin

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026
  2. 2Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
  3. 3Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
  4. 4Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  5. 5A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
  6. 6Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026

Found an error? Report a correction.